• 21 January, 2019
  • Keith Alm joined the ISSCR as chief operating officer in January 2019, after serving as a brand strategist and consultant for the society for nearly a decade. He’s worked with many of the organization's leaders on strategic positioning, communications, and partnerships.
    Full story
  • 13 December, 2018
  • In written and oral testimony before the U.S. House of Representatives Oversight and Government Reform Committee today, former ISSCR president Sally Temple describes fetal tissue research as essential in studying and developing therapies for cancer, HIV, Zika, tuberculous, and other devastating diseases.
    Full story
  • 26 November, 2018
  • Reports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.
    Full story
  • 16 November, 2018
  • The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk.
    Full story
  • ISSCR Comments on Horizon Europe

  • 2 October, 2018
  • The ISSCR has responded to the European Commission proposal and the European Parliament's amendments for Horizon Europe, the seven-year research and innovation funding program to follow Horizon 2020.
    Full story
  • ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research

  • 27 September, 2018
  • The ISSCR is troubled by the HHS decision to “conduct a comprehensive review of all fetal tissue research.” The directive appears to come after intensive lobbying efforts by special interest groups with the goals of delaying or curtailing scientific research that relies on fetal tissue.
    Full story
  • Douglas A. Melton Becomes President of the ISSCR

  • 22 June, 2018
  • The ISSCR is pleased to announce Douglas A. Melton, PhD, Harvard University, as the incoming president of the ISSCR and its board of directors. Melton assumed the post on 23 June, 2018, immediately following the 16th ISSCR Annual Meeting in Melbourne, Australia.
    Full story
  • ISSCR Announces New Editor-in-chief for Stem Cell Reports Journal

  • 20 June, 2018
  • The ISSCR has appointed Martin F. Pera, professor at the Jackson Laboratory, U.S., as the next editor-in-chief of Stem Cell Reports, the organization’s open-access journal. Pera will succeed Christine Mummery, who led the journal since its launch in 2013. Pera will assume the post in January, 2019.
    Full story
  • ISSCR Opposes Proposal to Restrict Fetal Tissue Research

  • 14 June, 2018
  • 6/14/2018 2:00:00 PM

    The ISSCR opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released a statement on the issue.
    Full story
  • ISSCR Announces Hamburg, Germany as Site of 2021 Annual Meeting

  • 23 May, 2018
  • The ISSCR will hold its 2021 annual meeting in Hamburg, Germany, the first time the organization will be meeting in that city. The meeting is expected to draw 4,000 stem cell researchers and professionals from around the globe to the Congress Center Hamburg, scheduled to open in 2019. The meeting will be held 23-26 June, 2021.
    Full story
  • ISSCR Responds to President Trump Signing 'Right to Try' Law

  • 4 June, 2018
  • 6/4/2018 4:00:00 AM

    The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
    Full story
  • ISSCR Applauds Federal Injunctions Against Stem Cell Clinics

  • 10 May, 2018
  • The ISSCR is pleased that federal prosecutors in the U.S. have taken action to halt the marketing and delivery of unproven stem cell treatments at clinics they allege are operating outside of FDA regulation.
    Full story
  • Active Support for Stem Cell Research Around the World

  • 7 May, 2018
  • Scientific progress requires that legislators and regulators around the world recognize and appreciate the value of research and actively support pro-science policies. The ISSCR, through its policy program, champions the advancement of stem cell research and its translation to medicine.
    Full story
  • ISSCR 2018 to Highlight Research Driving New Discoveries and Advances in Regenerative Medicine

  • 30 April, 2018
  • Progress in stem cell research and its translation to medicine is the focus of the International Society for Stem Cell Research annual meeting 20-23 June at the Melbourne Convention & Exhibition Centre in Melbourne, Australia.
    Full story
  • ISSCR Applauds Australia’s Move to Regulate Autologous Human Cell and Tissue Products

  • 26 April, 2018
  • The ISSCR appreciates the new framework proposed by Australia’s Therapeutic Goods Administration (TGA) for the regulation of human cell and tissue products that use a person’s own cells (‘autologous use’).
    Full story
  • Media Registration Open for ISSCR 2018 20-23 June, Melbourne, AUS

  • 21 March, 2018
  • Credentialed reporters can register and attend the 2018 annual meeting in Melbourne, Australia. They will have access to the many stem cell researchers and clinicians from around the world who will be discussing recent findings and progress that is driving development of stem cell treatments and cures for disease.
    Full story
  • ISSCR Announces Two New Science Communications & Education Managers

  • 4 January, 2018
  • The ISSCR has selected Christopher Barry, PhD, and Julie Perlin, PhD, to be Science Communications & Education Managers, beginning 3 January, 2018.
    Full story
  • ISSCR Remembers Hiromitsu “Hiro” Ogawa

  • 4 January, 2018
  • The ISSCR is saddened by the passing of Hiromitsu “Hiro” Ogawa, a generous and thoughtful man who was a great supporter of stem cell science and the ISSCR.
    Full story
  • ISSCR Applauds the FDA Announcement of New Guidelines for Cellular Therapies and Cell-based Tissue Products

  • 17 November, 2017
  • The ISSCR commends the U.S. Food and Drug Administration (FDA) for reaffirming its regulatory authority over stem cell biologics and clarifying the criteria that determine which cell-based products fall under its oversight. These guidance documents will provide greater transparency for patients, medical professionals, and law enforcement authorities, about the legal status of stem cell treatments in the U.S.
    Full story
  • ISSCR Applauds California Bill to Assist Stem Cell Patients

  • 4 October, 2017
  • A measure signed into law 3 October in the state of California, U.S., requires clinics to inform patients if they are using stem cell interventions that have not been approved by the Food and Drug Administration (FDA). ISSCR president Hans Clevers expresses support for the measure.
    Full story
    View All ISSCR News